Avacta has exclusive rights over the Affimer® technology intellectual property through a number of granted global patents and patents pending. Avacta requires no access to third party intellectual property for the discovery, development or manufacturing of Affimer molecules. The company continues to broaden its Affimer platform intellectual property, as well as generating application specific know-how and patentable inventions, through active R&D programmes.
This simple intellectual property position, in addition to the company's unique know-how and experience of the Affimer technology, lies at the core of our partnerships to develop innovative therapeutics, research tool and diagnostics.
For more information on Avacta’s IP portfolio, please contact us.